Cite

HARVARD Citation

    Yao, J. et al. (2021). Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. Endocrine-related cancer. 28 (3), pp. 161-172. [Online]. 
  
Back to record